Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05718232

SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) — SEARCH  

Advanced Hepatocellular Carcinoma Clinical Trial

Official title:
Stereotactic Body Radiation Therapy Plus Lenvatinib and Transarterial Chemoembolization for Advanced Primary Hepatocellular Carcinoma: A Phase 3, Multicentric, Randomized Controlled Trial

Clinical Trial Summary

This is a phase 3, multicentri, randomised, open label study. The purpose is to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) combined with transarterial chemoembolization (TACE) and lenvatinib (LEN) in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05718232
Study type Interventional
Source Sun Yat-sen University
Contact Ming Kuang, Ph.D.
Phone 008687755766
Email kuangm@mail.sysu.edu.cn
Status Not yet recruiting
Phase Phase 3
Start date March 2023
Completion date February 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Recruiting NCT05057845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT02632006 - Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT02638857 - Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT00752063 - Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma Phase 2
Completed NCT00517920 - Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT05797805 - A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Active, not recruiting NCT05070156 - B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Early Phase 1
Not yet recruiting NCT06092112 - A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma Early Phase 1
Recruiting NCT01214343 - Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC Phase 3
Completed NCT00999882 - Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients Phase 1
Withdrawn NCT00756782 - A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT00534664 - Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04503902 - Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Terminated NCT04777708 - BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Early Phase 1
Completed NCT04072679 - Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma Phase 1
Suspended NCT04066660 - Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) N/A
Withdrawn NCT05592197 - Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT N/A
Completed NCT02528643 - A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1